CD36 expression intensity on different subpopulations of circulating monocytes depending on the extent of subclinical atherosclerosis

封面

如何引用文章

全文:

详细

It is known that chronic activation of innate immunity and persistent low-intensity inflammation play a crucial role in the initiation and progression of atherosclerosis. It was found that atherogenic lipoproteins can act as inducers of the inflammatory response through ligand-receptor interaction with pattern-recognizing receptors of immunocompetent cells, such as CD36 (SR-B2) and Toll-like receptors. It is suggested that expression of CD36 on circulating monocytes may represent the burden of systemic atherosclerosis and, therefore, act as its diagnostic marker. The aim of the present study was to assess the intensity of CD36 expression on circulating monocytes of different subpopulations in patients without established cardiovascular disease (CVD) depending on the extent of subclinical atherosclerosis of peripheral arteries. One hundred patients without established atherosclerotic CVD, 49 (49.0%) men and 51 (51.0%) women, were included in the study. Monoclonal antibody conjugates were used to phenotype monocyte subpopulations. The expression of CD36 on CD14++CD16- monocytes (classical monocytes), CD14+CD16+ monocytes (intermediate monocytes), CD14+CD16++ monocytes (non-classical monocytes) was determined by the average fluorescence intensity. There was a statistically significant decrease in CD36 expression intensity on classical and non-classical monocytes with increasing number of vascular basins affected by atherosclerosis. A statistically significant decrease in CD36 expression intensity on classical and non-classical monocytes was found in the patients with two vascular beds lesions in comparison with patients with a single vascular bed lesion upon pairwise comparisons.

作者简介

I. Dolgushin

South-Ural State Medical University

Email: dol-ii@mail.ru
ORCID iD: 0000-0002-0901-8042

 PhD, MD (Medicine), Professor, Full Member, Russian Academy of Sciences, President, Head, Department of Microbiology, Virology, Immunology and Clinical Laboratory Diagnostics, Director, Research Institute of Immunology 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

V. Genkel

South Ural State Medical University

编辑信件的主要联系方式.
Email: henkel-07@mail.ru
ORCID iD: 0000-0001-5902-3803

PhD (Medicine), Associate Professor, Department for Propaedeutics of Internal Diseases 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

Phone: 7 (951) 441-70-61 

俄罗斯联邦

I. Baturina

South Ural State Medical University

Email: irisha_baturina@mail.ru
ORCID iD: 0000-0002-5960-4189

 PhD (Medicine), Senior Research Associate, Research Institute of Immunology 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

A. Savochkina

South Ural State Medical University

Email: alina7423@mail.ru
ORCID iD: 0000-0002-0536-0924

 PhD, MD (Medicine), Professor, Department of Microbiology, Virology, Immunology and Clinical Laboratory Diagnostics, Chief Research Associate, Research Institute of Immunology 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

A. Minasova

South Ural State Medical University

Email: pandora_anna@mail.ru
ORCID iD: 0000-0002-9084-0577

 PhD (Biology), Associate Professor, Department of Microbiology, Virology, Immunology and Clinical Laboratory Diagnostics 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

A. Kuznetsova

South Ural State Medical University

Email: kuzja321@mail.ru
ORCID iD: 0000-0002-1136-7284

 PhD (Medicine), Associate Professor, Department of Hospital Therapy 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

I. Shaposhnik

South Ural State Medical University

Email: shaposhnik@yandex.ru
ORCID iD: 0000-0002-7731-7730

 MD, PhD (Medicine), Professor, Head, Department for Propaedeutics of Internal Diseases 

454092, Russian Federation, Chelyabinsk, Vorovsky str., 64

俄罗斯联邦

参考

  1. Гусев Е.Ю., Зотова Н.В., Журавлева Ю.А., Черешнев В.А. Физиологическая и патогенетическая роль рецепторов-мусорщиков у человека // Медицинская иммунология, 2020. Т. 22, № 1. С. 7-48. doi: 10.15789/1563-0625-PAP-1893.
  2. Chandran J., Wadhwa N., Madhu S.V., Kumar R., Sharma S. Monocyte CD36 expression associates with atherosclerotic burden in diabetes mellitus. Diabetes Res. Clin. Pract., 2020, Vol. 163, 108156. doi: 10.1016/j.diabres.2020.108156.
  3. Gómez-Bañuelos E., Martín-Márquez B.T., Martínez-García E.A., Figueroa-Sanchez M., NuñezAtahualpa L., Rocha-Muñoz A.D., Sánchez-Hernández P.E., Navarro-Hernandez R.E., Madrigal-Ruiz P.M., SaldañaMillan A.A., Duran-Barragan S., Gonzalez-Lopez L., Gamez-Nava J.I., Vázquez-Del Mercado M. Low levels of CD36 in peripheral blood monocytes in subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study in a Mexican population. Biomed Res. Int., 2014, Vol. 2014, 736786. doi: 10.1155/2014/736786.
  4. Liberale L., Montecucco F., Tardif J.C., Libby P., Camici G.G. Inflamm-ageing: the role of inflamemation in age-dependent cardiovascular disease. Eur. Heart J., 2020, Vol. 41, no. 31, pp. 2974-2982.
  5. Park Y.M. CD36, a scavenger receptor implicated in atherosclerosis. Exp. Mol. Med., 2014, Vol., 46, no. 6, e99. doi: 10.1038/emm.2014.38.
  6. Piechota M., Banaszewska A., Dudziak J., Slomczynski M., Plewa R. Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes. Protein J., 2012, Vol. 31, no. 6, pp. 511-518.
  7. Tian K., Xu Y., Sahebkar A., Xu S. CD36 in atherosclerosis: pathophysiological mechanisms and therapeutic implications. Curr. Atheroscler. Rep., 2020, Vol. 22, no. 10, 59. doi: 10.1007/s11883-020-00870-8.
  8. Yassin L.M., Londoño J., Montoya G., De Sanctis J.B., Rojas M., Ramírez L.A., García L.F., Vásquez G. Atherosclerosis development in SLE patients is not determined by monocytes ability to bind/endocytose Ox-LDL. Autoimmunity, 2011, Vol. 44, no. 3, pp. 201-210.
  9. Yazgan B., Sozen E., Karademir B., Ustunsoy S., Ince U., Zarkovic N., Ozer N.K. CD36 expression in peripheral blood mononuclear cells reflects the onset of atherosclerosis. Biofactors, 2018, Vol. 44, no. 6, pp. 588-596.
  10. Zhao L., Varghese Z., Moorhead J.F., Chen Y., Ruan X.Z. CD36 and lipid metabolism in the evolution of atherosclerosis. Br. Med. Bull., 2018, Vol. 126, no. 1, pp. 101-112

补充文件

附件文件
动作
1. JATS XML

版权所有 © Dolgushin I.I., Genkel V.V., Baturina I.L., Savochkina A.Y., Minasova A.A., Kuznetsova A.S., Shaposhnik I.I., 2021

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##